SEVERINO MICHAEL 4
4 · AbbVie Inc. · Filed May 25, 2022
Insider Transaction Report
Form 4
AbbVie Inc.ABBV
SEVERINO MICHAEL
EVP, R&D and CSO
Transactions
- Exercise/Conversion
Common Stock, $0.01 par value
2022-05-23$114.36/sh+46,320$5,297,155→ 198,423 total - Exercise/Conversion
Common Stock, $0.01 par value
2022-05-23$105.92/sh+21,739$2,302,595→ 231,904 total - Exercise/Conversion
Option (Right to Buy)
2022-05-23$114.36/sh−46,320$5,297,155→ 0 totalExercise: $114.36From: 2019-02-15Exp: 2028-02-14→ Common Stock (46,320 underlying) - Exercise/Conversion
Option (Right to Buy)
2022-05-23$93.50/sh−11,742$1,097,877→ 38,188 totalExercise: $93.50From: 2021-02-20Exp: 2030-02-19→ Common Stock (11,742 underlying) - Exercise/Conversion
Option (Right to Buy)
2022-05-23$105.92/sh−21,739$2,302,595→ 43,478 totalExercise: $105.92From: 2022-02-18Exp: 2031-02-17→ Common Stock (21,739 underlying) - Sale
Common Stock, $0.01 par value
2022-05-23$150.79/sh−68,196$10,283,275→ 163,708 total - Exercise/Conversion
Common Stock, $0.01 par value
2022-05-23$93.50/sh+11,742$1,097,877→ 210,165 total - Sale
Common Stock, $0.01 par value
2022-05-23$151.53/sh−11,605$1,758,506→ 152,103 total
Footnotes (3)
- [F1]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.13 to $151.12 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.13 to $151.58 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.